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Persistent anemia is a known consequence of Par-
vovirus B19 (B19) infection following renal transplan-
tation. However, to date, no description of B19-related
hemophagocytic lymphohistiocytosis (HLH) exists in
renal transplant recipients. We report a 24-year-old
male kidney recipient, who presented with fever,
severe anemia and allograft dysfunction two years
following transplantation. Hyperferritinemia, hyper-
triglyceridemia, elevated serum lactate dehydroge-
nase, pancytopenia and fragmented red blood cells on
the peripheral blood were also noted. Bone marrow
examination revealed giant pronormoblasts and fre-
quent histiocytes with intracellular hematopoietic el-
ements, consistent with HLH. Renal allograft biopsy
revealed closure of the lumen of glomerular capillaries
and thickening of the capillary walls compatible with
thrombotic microangiopathy. The presence of anti-B19
IgM antibody and viral DNA in the patient’s serum (de-
tected by real-time PCR) confirmed an acute B19 infec-
tion. Following high-dose intravenous immunoglobu-
lin therapy, the anemia gradually resolved and renal
function improved. As far as we know, this is the first
report of B19-associated HLH and thrombotic microan-
giopathy in a renal transplant recipient.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a hetero-
geneous clinicopathological entity associated with uncon-
trolled and ineffective immune activation leading to cellular
damage and multiorgan dysfunction as well as excessive
activation of the benign macrophages in the bone marrow,
spleen and lymph nodes (1,2). The activated macrophages
then transform into histiocytes phagocytizing erythro-
cytes, leukocytes, platelets and their precursor cells lead-
ing to various degrees of cytopenia, hepatosplenomegaly
and lymphadenopathy. Excessive production of different
cytokines including tumor necrosis factor (TNF)-alpha,
interleukin-6, interleukin-8 and interferon-gamma are im-
plicated in the pathogenesis of HLH (2). HLH can develop
in patients with hereditary immune dysfunction, infections,
neoplastic or autoimmune diseases (1). A familial form of
HLH does also exist. The presence of hemophagocytosis in
the bone marrow, spleen or lymph nodes, elevated serum
lactic dehydrogenase (LDH >1000 IU/L), hyperferritinemia
(>500 ng/mL), hypertriglyceridemia (>3 mmol/L), hypofib-
rinogenemia (<1.5 g/L), low or absent natural killer cell cy-
totoxicity, elevated soluble IL-2 receptor (>2400 U/mL),
cytopenia affecting at least two cell lineages (platelets
<100 000/lL or neutrophils <1000/lL) are suggestive of
this entity (1–4).
Parvovirus B19 (B19) is the only member of the family
Parvoviridae. Infection with B19 is a known cause of ery-
thema infectiosum, polyarthropathy syndromes, erythroid
hypoplasia and aplastic anemia in healthy individuals (5).
In renal transplant recipients, B19 infection may enter the
body via the respiratory tree or transplanted organ, or may
be reactivated from a latent infection (6). This infection is
associated with refractory and recurrent anemia, glumeru-
lopathy, proteinuria, microscopic vasculitis, thrombotic mi-
croangiopathy (TMA), hepatitis and severe encephalitis in
renal transplant recipients (7–13). Herein, we report a re-
nal transplant recipient with severe anemia, allograft dys-
function, TMA and HLH two years following transplanta-
tion. Acute B19 infection was ascertained by positive anti-
B19 IgM titer and the presence of high-serum viral load.
To the best of our knowledge, this is the first report of
B19-associated HLH in a renal transplant recipient.
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Case Report
In April 2007, a 24-year-old male was admitted for a three-
week onset of fever and severe anemia. The patient had
received a living, unrelated renal transplantation two years
previously and was on triple immunosuppressive ther-
apy including cyclosporine (200 mg/day), mycophenolate
mofetile (2 gm/day) and prednisolone (5 mg/day). The base-
line blood cyclosporine level was 280 ng/mL, and the
serum creatinine level was 1.2 mg/dL. His past medical
history revealed the onset of postrenal transplant diabetes
mellitus three months earlier after which the patient had
received insulin. At that time, his hemoglobin level was
17.5 g/dL. The family history was unrevealing.
On physical examination, blood pressure was 100/60
mmHg and body temperature was 38◦C. The patient was
alert and oriented. No rash or icter was noted. Hep-
atosplenomegaly or lymphadenopathy was not found. The
physical examination was otherwise unremarkable. On ad-
mission laboratory findings are summarized in Table 1.
There was a normochromic-normocytic anemia. The pa-
tient received packed red blood cell infusion. Serum ferritin,
LDH and fasting triglyceride levels were elevated. Serum
creatinine level was 3 mg/dL. A urine dipstick test re-
vealed moderate proteinuria. A 24-hour urine volume was
Table 1: On admission laboratory findings in the present patient
Normal range
Level (for male)
Hemoglobin (g/dL) 5.5 13–18
White blood cell count
(lL−)
5200 3600–11 200











Serum ferritin (ng/mL) > 800 12–300
Fasting triglyceride
(mg/dL)






















2200 mL with a urine protein-to-creatinine ratio of 0.51.
Prothrombin and partial thromboplastin times were within
normal limits. Peripheral blood examination revealed fre-
quent helmet cells. Renal allograft Doppler ultrasonogra-
phy disclosed a normal size renal allograft with normal cor-
ticomedullary differentiation and echogenicity. Intra-renal
arterial resistive index was within normal limit. Upper gas-
trointestinal endoscopy was unrevealing. The platelet and
white blood cell count nadirs were 39 000/lL and 2400/lL
(53% polymorphonuclear cells) at days 5–7 of admission.
Serological studies for Epstein-Bar virus (EBV), hepatitis B,
C and E and human immunodeficiency virus (HIV) were
negative. Hepatitis B surface antigen was negative. Anti-
hepatitis A IgM antibody was negative and IgG antibody
was positive, consistent with previous infection. A neg-
ative anticytomegalovirus IgM and positive IgG titer were
also detected (anti-CMV IgG also was positive before trans-
plantation). Serological tests for parovirus B-19 infection
were performed (using enzyme-linked immunosorbent as-
say; DRG instruments, GmbH, Germany), which was posi-
tive for anti-B19 IgM antibody. Subsequently, B19 viral DNA
was detected in the serum by nested polymerase chain re-
action (PCR) using the major capsid protein (VP2)-encoding
sequence of B19 as described by Cassinotti et al. (14). The
real-time PCR (with Artus RealArtTM Parvo B19 LC PCR kit)
revealed a viral load higher than 104 IU/L.
Bone marrow aspiration and biopsy disclosed erythroid
immaturity with a left shift and occasional giant pronor-
moblasts with dark-blue cytoplasm (Figure 1). Myeloid and
megakaryocytic linages were normal in appearance. Nu-
merous large histiocytes with engulfed lymphocyte, poly-
morphonuclear and red blood cells were prominent, which
Figure 1: Bone marrow containing giant pronormoblasts
(star) with dark-blue cytoplasm (Giemsa, 1000×).
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Figure 2: Bone marrow histiocyte (star) with intracellular
hematopoietic elements (Giemsa, 1000×).
were suggestive of hemophagocytosis (Figure 2). A per-
cutaneous renal allograft needle biopsy was performed
at day 3 of admission. Light microscopic examination of
renal biopsy specimens (Figure 3) revealed the luminal
narrowing of glomerular capillaries, thickening of glomeru-
lar capillary walls and duplication of the glomerular base-
ment membrane, endothelial swelling and some areas
of capillary loop closure, all of which were compatible
with subacute glomerular involvement due to thrombotic
microangiopathy.
Figure 3: Glumerulus showing closed capillary lumens, thick-
ening of capillary walls and duplication of the glomerular
basement membrane.
Subsequently, high-dose intravenous immunoglobulin
(IVIG, 400 mg/kg/day for five days) was administered at
day 8 of admission. The prescribed dose of mycopheno-
late mofetil was reduced to 1 gm/day. The patient’s gen-
eral condition gradually improved and his fever subsided.
On day 20 of admission, the patient’s serum creatinine
declined to 2 mg/dL and hemoglobin level increased to
9.5 mg/dL. On a follow-up visit, three months following
discharge, hemoglobin was 14 g/dL, WBC count 9000/lL
and platelet count 234 000/lL. Serum creatinine level was
1.2 mg/dL. Serological studies revealed a positive anti-B19
IgG and negative IgM titers. A 2 g/day dose of MMF dosage
was restarted and the patient was scheduled to have reg-
ular follow-up visits.
Discussion
In the present case, the diagnosis of HLH was made by the
suggestive bone marrow and laboratory findings (2,15,16).
Elevated serum ferritin, hypertriglyceridemia, severe ane-
mia and decreased platelet count were also compatible
with HLH (1,3). The diagnosis of B19 infection was primar-
ily obtained by the presence of anti-B19 IgM antibodies
and viral DNA in the patient’s serum. Additionally, the pres-
ence of fragmented red blood cells in the peripheral blood,
hemolysis and renal histopathology were consistent with
TMA. The temporal association of HLH, TMA and positive
B19 serology and PCR led us to attribute the present sce-
nario to an acute B19 infection.
The natural history and outcome of infection-associated
HLH may depend on the inciting pathogen. EBV is the most
common triggering agent (2). In a series of 219 children
with infection-associated HLH, EBV infection was associ-
ated with a higher mortality (17). Usually treatment of the
triggering infections is ineffective and severe cases may
require chemotherapy and bone marrow transplant (2). Cy-
tomegalovirus has been described as a cause of HLH in
transplant recipients and is associated with a poor outcome
(2,18). However, recovery has been reported following spe-
cific anticytomegalovirus therapy (19). HLH due to B19
infection carries a better prognosis compared with other
virus-associated HLH and most patients with this compli-
cation may survive without specific therapy (2). The most
common underlying disease in B19 related HLH is heredi-
tary spherocytosis (2).
Since the first report of B19 associated HLH (20), few
similar cases have been described (21–24). To date about
30 such cases have been reported in children and adults.
None of these has occurred following kidney transplanta-
tion. In a series of 17 renal transplant recipients with HLH,
nine patients had viral infection with cytomegalovirus,
Epstein-Barr virus and human herpesvirus 6 and 8, while
no case of B19 infection was reported (25). Infections
with BK virus, Mycobacterium tuberculosis, Toxoplasma,
Escherichia coli, Bartonella henselae and Pneumocystis
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carinii have also been reported as the cause of HLH fol-
lowing renal transplantation (25–28). Hence, performing an
extensive workup for the infectious causes of HLH is nec-
essary as some infections can trigger HLH and the man-
agement is different depending on the case.
In the present patient, renal allograft histopathology was
compatible with TMA. This type of B19-related glomeru-
lopathy has been reported by Murer et al. (7). Collapsing
glomerulopathy, minimal change disease and TMA with
nephrotic syndrome have been described in a small series
of HLH patients (29). It has been proposed that in HLH, high
levels of inflammatory cytokines particularly TNF-alpha can
injure podocytes leading to glomerular collapse and tubu-
lar necrosis with subsequent proteinuria and renal dys-
function (29–31). In the present patient, anemia, protein-
uria and renal allograft function improved with high-dose
IVIG therapy. The efficacy of high-dose IVIG in the eradica-
tion of postrenal transplant B19 infection has been demon-
strated previously (9,32). Positive seroconversion and long-
term remission of recurrent anemia with IVIG therapy has
been reported in a renal transplant recipient despite per-
sistence of viral genome (33). Nonetheless, in a series of
13 renal transplant recipients with HLH, complete recov-
ery was obtained in those received high-dose IVIG therapy
(26).
Finally, diagnosis of B19 infection requires a high index
of suspicion. Clinicians should consider this infection as
a potential cause of HLH and TMA in renal transplant
recipients.
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